Samsung Bioepis partners with NIPRO for multiple biosimilars in Japan

Samsung Bioepis has entered into a license, development and commercialization agreement with NIPRO for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan.

Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan.

“This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,” said Kyung-Ah Kim, president and CEO of Samsung Bioepis. 

[Read more: AAM: IRA hampers generic, biosimilar drug competition]

Kim added, “We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.”